Long-term management of patients with end-stage lung diseases
Authors:
- 1 June 2017
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 31 (2) , 167-178
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Endurance Time Is the Most Responsive Exercise Measurement in Idiopathic Pulmonary FibrosisRespiratory Care, 2013
- Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trialsThe Lancet Respiratory Medicine, 2013
- Anti-acid treatment for idiopathic pulmonary fibrosisThe Lancet Respiratory Medicine, 2013
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patientEuropean Respiratory Review, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosisEuropean Respiratory Journal, 2007
- High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2006
- Idiopathic Pulmonary Fibrosis: Impact of Oxygen and Colchicine, Prednisone, or No Therapy on SurvivalAmerican Journal of Respiratory and Critical Care Medicine, 2000